

a1  
cont

3. (amended) The method of claim 2 wherein said protein or peptide is selected from the group consisting of prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP) [PSA, PSMA, PAP] and [a fragment thereof] an immunologically effective portion thereof.

---

a2

6. (amended) The method of claim 1 wherein said composition is administered to said subject [is in a "neoadjuvant" setting] prior to surgical excision of said prostate tumor.

---

a3

8. (amended) A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors in a subject which comprises [an active] an ingredient which is active to elicit said immune response, is formulated for parenteral administration and is  
an expression system capable of generating *in situ* an antigen overrepresented on the prostate gland with respect to other tissues or an immunologically effective portion thereof.

9. (amended) The vaccine of claim 8 wherein said antigen is selected from the group consisting of prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP) [PSA, PSMA, PAP] and [a] an immunologically effective portion thereof.

---

a4

14. (amended) The vaccine of claim 8 wherein said expression system consists essentially of DNA encoding said antigen or said portion or wherein said expression system comprises a living expression vector.

15. (amended) A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors in subject which comprises [as active] an ingredient which is active to elicit said immune response, is formulated for parenteral administration and is

an antiidiotypic antibody or [fragment] immunologically effective portion thereof which mimics an antigen overrepresented on the prostate gland with respect to other tissues [or an immunologically effective portion thereof].

16. (amended) The vaccine of claim 15 wherein said antigen is selected from the group consisting of prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP) [PSA, PSMA, PAP] and [a] an immunologically effective portion thereof.

21. (amended) A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors in a subject which comprises [as active] an ingredient which is active to elicit said immune response, is formulated for parenteral administration and comprises

at least one antigen overrepresented on the prostate gland with respect to other tissues or an immunologically effective portion thereof,

wherein said [active] ingredient is encapsulated in or coupled to a liposome.

22. (amended) A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors in a subject which comprises at least two [active] ingredients which are active to elicit said immune

response and are formulated for parenteral administration,  
wherein each ingredient is selected from the group  
consisting of

an antigen overrepresented on the prostate gland  
with respect to other tissues or an immunologically  
effective portion thereof;

an expression system capable of generating *in situ*  
said antigen or said portion; and

an antiidiotypic antibody or [fragment] an  
immunologically effective portion thereof which mimics said  
antigen [or portion].

23. (amended) The vaccine of claim 22 wherein  
said antigen is selected from the group consisting of PSA,  
PSMA, PAP and [a] an immunologically effective portion  
thereof.

28. (amended) A pharmaceutical or veterinary  
vaccine for eliciting an antitumor immune response to  
prostate tumors which comprises [as active] an ingredient  
which is active to elicit said immune response, is  
formulated for parenteral administration, and comprises at  
least one immunologically effective portion of an antigen  
overrepresented on the prostate gland with respect to other  
tissues said portion being less than the complete antigen.

29. (amended) The vaccine of claim 28 wherein  
said antigen is selected from the group consisting of  
prostate specific antigen (PSA), prostate specific membrane  
antigen (PSMA), prostatic acid phosphatase (PAP) [PSA, PSMA,  
PAP].